Sector News

Novartis follows brand offloading trend, selling drugs in Japan to Sun

March 30, 2016
Life sciences

India’s Sun Pharmaceutical is the beneficiary of one Big Pharma’s trends: companies offloading generally older brands to pick up some cash and keep sales folks focused on key treatment areas.

In this case, it is Novartis that is shedding products, having sold more than a dozen prescription brands to Sun in Japan, a market where Novartis has had its troubles.

Sun Tuesday said it will acquire 14 established prescription brands from Novartis for $293 million. The drugs, which span a number of therapeutic areas, had annual sales of about $160 million. Novartis will continue to distribute them until Sun arranges marketing authorizations and gets a local distributor.

“This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future,” Sun Managing Director Dilip Shanghvi said in a statement.

For Novartis, it is following a path well-trod by Merck & Co.,, GlaxoSmithKline, Abbott Laboratories and others, who have hived off older brands that no longer fit into more focused goals, picking up billions of dollars in the process. AstraZeneca CEO Pascal Soriot has made an art of selling marketing rights to one or two products in specific markets. With AstraZeneca desperate for cash while Soriot tries to work some turnaround magic at the U.K. pharma, the company has done a series of deals for its “non-core assets.”

Most recently, AstraZeneca sold ProStrakan the rights to market a drug for opioid-induced constipation in Europe, Iceland, Norway, Switzerland and Liechtenstein. AstraZeneca gets $70 million and royalties in that deal. Last month, it pawned the rights to a couple of heart drugs to a Chinese company, raising $500 million while giving up what last year amounted to $246 million in revenue.

Up to now, Novartis Chairman Joerg Reinhardt has taken a more wholesale approach to unloading assets to narrow the Swiss drugmaker’s focus. In 2014, Novartis worked a deal to trade assets with GSK and also sold off the company’s animal health unit to Merck. The deals were valued at about $25 billion.

The Japan deal with Sun pales by comparison but comes at a time when the Novartis brand has been tarnished in that country by a couple of scandals. In 2014, Novartis’ Japanese affiliate was indicted along with a former employee for allegedly manipulating data in clinical trials for a blockbuster heart drug. Then in February 2015, the government suspended Novartis operations for 15 days as punishment for failing to properly report drug side effects.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach